Tsuji Takahiro, Miura Masayoshi, Yanai Mitsuru, Itami Hiroe, Ishii Yasushi, Akimoto Mayuko, Fukasawa Yuichiro
Department of Pathology, Sapporo City General Hospital.
Departments of Renal Transplant Surgery and Urology, Sapporo Hokuyu Hospital, Sapporo, Japan.
Nephrology (Carlton). 2016 Jul;21 Suppl 1:44-7. doi: 10.1111/nep.12773.
Proliferative glomerulonephritis with monoclonal immunoglobulin G (IgG) deposits (PGNMID) has recently been described in cases with glomerular disease. Only 16 cases of recurrent or de novo PGNMID have been reported in the transplanted kidney. Here we report a case of de novo PGNMID in a renal allograft diagnosed in the early stage by protocol biopsy. A 41-year-old male with end-stage kidney disease caused by focal glomerular sclerosis received a living-related kidney transplant. The post-transplantation course was stable, except for an early episode of acute T cell-mediated rejection. Mesangial C1q deposition was found on the 3-year protocol biopsy. On the 4-year protocol biopsy, mild mesangioproliferative changes and deposition of IgG, C1q, C3, IgG1, and κ light chain were evident, confirming the diagnosis of PGNMID of the IgG1κ subtype. Furthermore, mild proteinuria was detected at that time. Because a subsequent haematological examination revealed high copy number Epstein-Barr virus (EBV) DNA and free κ light chain in blood, the post-transplant lymphoproliferative disorder (PTLD) was suspected. Mycophenolate mofetil (MMF) was discontinued and rituximab was administered for the treatment of PTLD; subsequently, the improvement in proteinuria and serum creatinine was found 2 months after rituximab administration.
伴有单克隆免疫球蛋白G(IgG)沉积的增殖性肾小球肾炎(PGNMID)最近在肾小球疾病病例中被描述。移植肾中仅报告了16例复发性或新发PGNMID。在此,我们报告一例通过方案活检在早期诊断的同种异体移植肾新发PGNMID病例。一名因局灶性肾小球硬化导致终末期肾病的41岁男性接受了亲属活体肾移植。移植后过程稳定,除了早期发生的急性T细胞介导的排斥反应。在3年方案活检时发现系膜C1q沉积。在4年方案活检时,可见轻度系膜增生性改变以及IgG、C1q、C3、IgG1和κ轻链沉积,确诊为IgG1κ亚型的PGNMID。此外,当时检测到轻度蛋白尿。由于随后的血液学检查显示血液中爱泼斯坦-巴尔病毒(EBV)DNA拷贝数高且存在游离κ轻链,怀疑发生了移植后淋巴增殖性疾病(PTLD)。停用霉酚酸酯(MMF)并给予利妥昔单抗治疗PTLD;随后,在给予利妥昔单抗2个月后发现蛋白尿和血清肌酐有所改善。